Alembic Pharma’s arm receives USFDA approval for Fenofibrate Tablets

12 Feb 2019

Alembic Pharmaceuticals’ wholly owned step down subsidiary -- Orit Laboratories LLC has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Fenofibrate Tablets USP, 54 mg and 160 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Tricor Tablets, 54 mg and 160 mg, of AbbVie Inc. (AbbVie)

Fenofibrate Tablets USP, 54 mg and 160 mg are indicated as an adjunct to diet to reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidaemia and for treatment of adult patients with severe hypertriglyceridemia.

Fenofibrate Tablets USP, 54 mg and 160 mg have an estimated market size of $92 million for twelve months ending December 2018 according to IQVIA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Related Alembic Pharmaceuticals Ltd. Links:

Alembic Pharma Share Price

551.00 3.50 (0.64%) Nov 19, 13:47
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 426.20
Lupin 749.00
Dr. Reddys Lab 2737.00
Piramal Enterprises 1769.00
Cadila Healthcare 242.00
View more..
Sensex vs Alembic Pharma
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback

8055769463

8055769463